Youngevity International Inc (NASDAQ:YGYI) had a decrease of 2.17% in short interest. YGYI’s SI was 548,800 shares in April as released by FINRA. Its down 2.17% from 561,000 shares previously. With 426,400 avg volume, 1 days are for Youngevity International Inc (NASDAQ:YGYI)’s short sellers to cover YGYI’s short positions. The SI to Youngevity International Inc’s float is 7.52%. The stock increased 3.72% or $0.2 during the last trading session, reaching $5.57. About 47,859 shares traded. Youngevity International, Inc. (NASDAQ:YGYI) has risen 55.01% since April 16, 2018 and is uptrending. It has outperformed by 50.64% the S&P500. Some Historical YGYI News: 25/04/2018 – Youngevity Announces Asia Convention Event Is Being Held Next Month in Malaysia; 10/04/2018 – CLR Roasters Increases Capacity on Single Serve Production Line; 06/03/2018 YOUNGEVITY INTERNATIONAL COMPLETES ACQUISITION of VIAVIENTE; 29/03/2018 – YOUNGEVITY INTERNATIONAL INC QTRLY SHR LOSS $0.35; 14/05/2018 – YOUNGEVITY INTERNATIONAL INC QTRLY SHR LOSS $0.13

The stock of MEDNAX, Inc. (NYSE:MD) hit a new 52-week low and has $25.30 target or 5.00% below today’s $26.63 share price. The 6 months bearish chart indicates high risk for the $2.29 billion company. The 1-year low was reported on Apr, 16 by . If the $25.30 price target is reached, the company will be worth $114.35M less. The stock decreased 3.37% or $0.93 during the last trading session, reaching $26.63. About 592,664 shares traded. MEDNAX, Inc. (NYSE:MD) has declined 39.48% since April 16, 2018 and is downtrending. It has underperformed by 43.85% the S&P500. Some Historical MD News: 21/03/2018 – MEDNAX BUYS PEDIATRIC OPHTHALMOLOGY PRACTICE IN WASHINGTON; 20/04/2018 – DJ MEDNAX Inc, Inst Holders, 1Q 2018 (MD); 01/05/2018 – MEDNAX EXECUTIVE MAKES COMMENT ON EARNINGS CONFERENCE CALL; 16/05/2018 – Mednax Presenting at Bank of America Conference Tomorrow; 27/03/2018 – MEDNAX Announces Expansion of Radiology Practices; 02/04/2018 – MEDNAX INC – WITH ACQUISITION, FOUR PHYSICIAN GROUP PRACTICES HAVE BECOME PART OF MEDNAX IN 2018; 08/03/2018 – HELLMAN & FRIEDMAN IS ALSO SAID TO MAKE INDICATIVE MEDNAX BID; 26/04/2018 – Mednax process on life support, sources say [20:30 BST26 Apr 2018] [Proprietary] []; 08/03/2018 – MEDNAX, CARLYLE, TPG AND HELLMAN & FRIEDMAN DECLINED TO COMMENT; 02/04/2018 – MD SEES CHILDREN’S UROLOGY ASSOCIATES BUY TO ADD TO EARNINGS

MEDNAX, Inc., together with its subsidiaries, provides neonatal, anesthesia, maternal-fetal, and other pediatric subspecialties physician services in the United States and Puerto Rico. The company has market cap of $2.29 billion. The firm offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care; and acute and chronic pain management services. It has a 9.09 P/E ratio. It also provides maternal-fetal care, including inpatient and office clinical care to expectant mothers and their unborn babies through maternal-fetal medicine subspecialists, as well as obstetricians and other clinicians consisting of maternal-fetal nurse practitioners, certified nurse mid-wives, ultrasonographers, and genetic counselors.

More recent MEDNAX, Inc. (NYSE:MD) news were published by: Bizjournals.com which released: “Atrium Health CEO shares updates on big transitions from 2018 – Charlotte Business Journal” on March 26, 2019. Also Businesswire.com published the news titled: “MEDNAX Announces Board of Directors Nominees – Business Wire” on March 28, 2019. Foxbusiness.com‘s news article titled: “5 Must-See Highlights From Delta Air Lines’ Q1 Earnings Call – Fox Business” with publication date: April 16, 2019 was also an interesting one.

Among 6 analysts covering Mednax (NYSE:MD), 2 have Buy rating, 1 Sell and 3 Hold. Therefore 33% are positive. Mednax has $50 highest and $31 lowest target. $38’s average target is 42.70% above currents $26.63 stock price. Mednax had 10 analyst reports since October 19, 2018 according to SRatingsIntel. The firm has “Sell” rating by UBS given on Monday, February 25. BMO Capital Markets maintained MEDNAX, Inc. (NYSE:MD) rating on Friday, November 2. BMO Capital Markets has “Market Perform” rating and $43 target. The rating was maintained by Robert W. Baird on Friday, November 2 with “Neutral”. The firm earned “Outperform” rating on Tuesday, November 6 by Credit Suisse. The firm earned “Buy” rating on Tuesday, January 15 by Citigroup. The firm has “Outperform” rating by Credit Suisse given on Wednesday, February 13. On Friday, October 19 the stock rating was maintained by Robert W. Baird with “Neutral”.

Analysts await MEDNAX, Inc. (NYSE:MD) to report earnings on April, 29. They expect $0.63 EPS, down 22.22% or $0.18 from last year’s $0.81 per share. MD’s profit will be $54.10M for 10.57 P/E if the $0.63 EPS becomes a reality. After $0.84 actual EPS reported by MEDNAX, Inc. for the previous quarter, Wall Street now forecasts -25.00% negative EPS growth.

Youngevity International, Inc. develops and distributes health and nutrition related services and products through independent direct selling network in the United States and internationally. The company has market cap of $153.49 million. It operates through two divisions, Direct Selling and Commercial Coffee. It currently has negative earnings. The firm offers approximately 5,000 products, including nutritional supplements; sports and energy drinks; health and wellness products; weight loss products; lifestyle products, such as spa, bath, home, and garden products; gourmet coffee; apparel and fashion accessories; skincare and cosmetics; lifestyle services; digital products comprising scrap books and memory books, packaged foods, pharmacy discount cards, and clothing and jewelry lines; pet care products; telecare health services; and business lending services.